TGFβ in Cancer
By J. Massagué. Cell, 2008
3,779 citations recorded by the source corpus.
The transforming growth factor β (TGFβ) signaling pathway is a key player in metazoan biology, and its misregulation can result in tumor development. The regulatory cytokine TGFβ exerts tumor-suppressive effects that cancer cells must elude for malignant evolution. Yet, paradoxically, TGFβ also modulates processes such as cell invasion, immune regulation, and microenvironment modification that cancer cells may exploit to their advantage. Consequently, the output of a TGFβ response is highly contextual throughout development, across different tissues, and also in cancer. The mechanistic basis and clinical relevance of TGFβ’s role in cancer is becoming increasingly clear, paving the way for a better understanding of the complexity and therapeutic potential of this pathway.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/22e77628f3494e54f1713fc7265bf7ccff836726
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells (2009, neutral): “The role of cytokines in cancer has been well studied (Massague, 2008; Naugler and Karin, 2008), particularly in breast cancer (Nicolini et al.”
- A human functional protein interaction network and its application to cancer data analysis (2010, neutral): “In cancer, the TGFβ signaling network functions in complex ways to both suppress early tumor growth and promote late stage progression [4].”
- Mutant p53 gain-of-function in cancer. (2010, background): “…stages of the process, it serves as a tumor suppressor, strongly inhibiting the proliferation of epithelial cells; however, at advanced stages of the disease, it can turn into a potent driver of tumor spread and metastasis, severely worsening patient prognosis (Derynck et al. 2001; Massague 2008).”
- The Blood-Testis Barrier and Its Implications for Male Contraception (2012, background): “This protein complex, in turn, recruits other adaptors, mediating different signaling pathways downstream, involving different GTPases and mitogenactivated protein kinases (MAPKs), and regulating an array of cellular events and functions under normal and pathological conditions, including spermatoge”
- Hallmarks of cancer: the next generation. (2011, positive): “TGF-b is best known for its antiproliferative effects, and evasion by cancer cells of these effects is now appreciated to be far more elaborate than simple shutdown of its signaling circuitry (Ikush-ima and Miyazono, 2010; Massague´, 2008; Bierie and Moses, 2006).”
- A Pleiotropically Acting microRNA, miR-31, Inhibits Breast Cancer Metastasis (2009, positive): “Such duality of action is not unprecedented (Massagué, 2008) and is consistent with notions that metastasisand tumorigenesis-enabling attributes can be biologically distinct and acquired via independent selective pressures during malignant progression.”
- The essence of senescence. (2010, background): “A classic example is the pro- or anti-proliferative effect of TGFb on tumor cells as a function of the stage of tumorigenesis (Massagué 2008).”